Back to search
FDAFDA · Food and drugs·Recall number D-0181-2023

Advil (ibuprofen) Tablets, 200 mg, packaged as a) 360-count bottles (UPC 3 0573 0154 60 4), and b) 200-count bottles (UPC 3 0573 0154 21 5), Pfizer, Madison, NJ 07940

Published February 1, 2023 · Recall initiated: December 6, 2022

Summary

FDA records drug Class I recall D-0181-2023, published February 1, 2023 and initiated December 6, 2022. Recalling firm: Glaxosmithkline Consumer Healthcare Holdings DBA Haleon; Status: Terminated; Reported quantity: 321,246 tablets; Lot: a) Lots EJ2218, EJ2219, EJ2220, Exp 09/2023; b) Lot 953D, Exp 05/2025. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Glaxosmithkline Consumer Healthcare Holdings DBA Haleon
Distributor
Nationwide in the USA.
Lot
a) Lots EJ2218, EJ2219, EJ2220, Exp 09/2023; b) Lot 953D, Exp 05/2025
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Advil (ibuprofen) Tablets, 200 mg, packaged as a) 360-count bottles (UPC 3 0573 0154 60 4), and b) 200-count bottles (UPC 3 0573 0154 21 5), Pfizer, Madison, NJ 07940 recalled?

Yes. FDA published recall D-0181-2023 on February 1, 2023. Reported hazard: Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

What should I do if I have this product?

Voluntary: Firm initiated · Letter